The FDA granted an Emergency Use Authorization for ALung’s Hemolung respiratory-assist system for treating COVID-19 patients.

The device offers ultralow-flow removal of carbon dioxide that uses a dual-lumen catheter inserted in the patient’s femoral or jugular vein, providing partial lung support independent of the lungs.

The system is an alternative to invasive mechanical ventilation for acute respiratory failure patients. It consists of a catheter and a single-use disposable cartridge that can be used continuously for up to a week.